Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-09
2007-10-09
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S217030, C514S217020, C540S523000, C540S524000, C540S531000
Reexamination Certificate
active
10311369
ABSTRACT:
The invention relates to novel compounds which bind to integrin receptors, their use as ligands of integrin receptors, in particular as ligands of the αvβ3integrin receptor, their use, and pharmaceutical preparations comprising these compounds.
REFERENCES:
patent: 5565449 (1996-10-01), Blackburn et al.
patent: 6514964 (2003-02-01), Chen et al.
patent: 19653645 (1998-06-01), None
patent: 540334 (1993-05-01), None
patent: 908764 (1999-04-01), None
patent: WO93.08174 (1993-04-01), None
patent: WO96/06087 (1996-02-01), None
patent: WO96/26190 (1996-08-01), None
patent: WO97/24122 (1997-07-01), None
patent: WO97/24124 (1997-07-01), None
patent: WO98/02432 (1998-01-01), None
patent: WO98/14192 (1998-04-01), None
patent: WO99/05107 (1999-02-01), None
patent: WO99/06049 (1999-02-01), None
patent: WO99/11626 (1999-03-01), None
patent: WO 01/10847 (2001-02-01), None
patent: WO 01/23357 (2001-04-01), None
Basic and Clinical Pharmacology, 7th Edition, 1998, Bertram G. Katzung, pp. 881-884.
Miller et al, “Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic” Journal of Medicinal Chemstry, vol. 43, pp. 22-26 (2000).
Badger et al, “Disease-Modifying Activity of SB 273005, an Orally Active Nonpeptide αvβ3 (Vltronectin Receptor) Antagonist, in Rat Adjuvant-Induced Arthritis” Arthritis & Rheumatism, vol. 44(1), pp. 128-137 (2001).
Lark et al, “Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovarectomized Rat” Journal of Bone and Mineral Research, vol. 16(2), pp. 319-327 (2001).
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
E. Ruoslahi et al. Cell 1986, 44, 517-518.
E. Ruoslathi et al., Science 1987, 238, 491-497.
L. Piali, J. Cell Biol. 1995, 130, 451-460.
C.D. Buckley et al., J. Cell Science 1996, 109, 437-445.
M.L. Kireeva et al., J. Biol. Chem. 1998, 273, 3090-3096.
M. Aumailley et al., FEBS Letts. 1991, 291, 50-54.
J.W. Smith et al., J. Biol. Chem. 1990, 265, 12267-12271.
M. Pfaff et al., J. Biol. Chem. 1994, 269, 20233-20238.
D.A. Cheresh et al., J. Biol. Chem. 1987, 262, 17703-17711.
K.C. Nicolaou et al., Bioorg. Med. Chem. 1998, 6, 1185-1208.
Geneste Hervé
Graef Claudia Isabella
Hornberger Wilfried
Kling Andreas
Lange Udo
Abbott & GmbH & Co. KG
Tucker Zachary C
Wood Phillips Katz Clark & Mortimer
LandOfFree
Integrin ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3898661